Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Byung-Sik | - |
dc.contributor.author | Min, Gi-June | - |
dc.contributor.author | Park, Sung-Soo | - |
dc.contributor.author | Yoon, Seok Yoon | - |
dc.contributor.author | Park, Silvia | - |
dc.contributor.author | Jeon, Young-Woo | - |
dc.contributor.author | Shin, Seung-Hwan | - |
dc.contributor.author | Yahng, Seung-Ah | - |
dc.contributor.author | Yoon, Jae-Ho | - |
dc.contributor.author | Lee, Sung-Eun | - |
dc.contributor.author | Eom, Ki-Seong | - |
dc.contributor.author | Kim, Yoo-Jin | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Cho, Seok-Goo | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.contributor.author | Lee, Jong Wook | - |
dc.contributor.author | Kim, Hee-Je | - |
dc.contributor.author | Lee, Seok | - |
dc.date.accessioned | 2022-06-03T05:40:05Z | - |
dc.date.available | 2022-06-03T05:40:05Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 0361-8609 | - |
dc.identifier.issn | 1096-8652 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20924 | - |
dc.description.abstract | Despite the proven efficacy of anti-T-cell or antithymocyte globulin (ATG) for chronic graft-versus-host disease (GVHD) prevention in transplantation from an unrelated donor, dosing protocols and the effects of ATG on relapse and infection remain controversial. In the setting of transplantation from an HLA-matched sibling (MSD-T), few randomized studies have been conducted. We conducted a prospective, single-center, open-label, randomized study of low-dose thymoglobulin (2.5 mg/kg) for chronic GVHD prevention. A total of 120 patients with acute leukemia were randomly assigned in a 1:1 ratio. After a median follow-up of 27 months, the cumulative incidence of chronic GVHD in the ATG and non-ATG groups was 25.0% and 65.4% (p < 0.001), respectively. The ATG group had an increased relapse rate compared with the non-ATG-group (20.0% vs. 9.3%; p = 0.055), with risks that differed according to cytogenetic subgroup (high-risk, 29.6% vs. 9.3%, p = 0.042; non-high-risk, 12.2% vs. 9.2%, p = 0.596). Chronic GVHD-free and relapse-free survival (cGRFS) was higher in the ATG group (46.7% vs. 19.4%; p = 0.070), and the difference was significant in a cytogenetic non-high-risk subgroup (45.5% vs. 0%; p = 0.038). No differences were observed in other survival outcomes. Improved physical components in quality-of-life scores were observed in the ATG group at 12 months after transplantation. A higher rate of Epstein-Barr virus reactivation was observed in the ATG group (21.8% vs. 5.1%; p = 0.013), whereas no between-group differences for other complications. In conclusion, the low-dose thymoglobulin effectively prevented chronic GVHD in MSD-T, resulting in improvement in quality-of-life and cGRFS, whereas the necessity of caution for high-risk acute leukemia. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1002/ajh.26320 | - |
dc.identifier.wosid | 000689721300001 | - |
dc.identifier.bibliographicCitation | American Journal of Hematology, v.96, no.11, pp 1441 - 1449 | - |
dc.citation.title | American Journal of Hematology | - |
dc.citation.volume | 96 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1441 | - |
dc.citation.endPage | 1449 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | HEMATOPOIETIC-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | ANTI-THYMOCYTE GLOBULIN | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | UNRELATED DONORS | - |
dc.subject.keywordPlus | HEMATOLOGICAL MALIGNANCIES | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | ANTITHYMOCYTE GLOBULIN | - |
dc.subject.keywordPlus | PROPHYLAXIS | - |
dc.subject.keywordPlus | PHASE-3 | - |
dc.subject.keywordPlus | MULTICENTER | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.